CPAX and POC troponin testing device for patients with heart disease and cognitive impairment – NHS Innovation Service (ISSN 2753-8176 (online))

1. Ana Pedro

1.Gwyntwr1386 Pharmacy, Regus Chester Business Park, Heronsway, Chester, CH49QR, UK. info@gwyntwr1386.com

We concluded that most MCA users are elderly patients. Also, most of the patients suffer of combined cardiovascular disease. We intend to do an assessment of feasibility about providing a new online clinical delivery and treatment monitoring service for the NHS based on the CpaX medication management program from Jones Healthcare group in Canada coupled with a POC troponin test in helping patients with cognitive impairment and/or heart disease taking their medication properly.

Is your innovation relevant to any of the following areas?

Independence and prevention Digitalising the system Improving system flow Operational excellence Patient activation and self-care Patient safety and quality improvement Workforce resource optimisation Net zero NHS or greener innovation

In which care settings is your innovation relevant?

Acute trust - inpatient Acute trust - outpatient Care homes or care setting Pharmacies Primary care Social care Third sector organisations Urgent and emergency

What is the main purpose of your innovation?

Monitoring a condition, treatment or therapy

What problem is your innovation trying to solve?

Proper and timely medicine taking and timely monitoring of medication effects

Give an overview of how your innovation works

In an automated fashion, this will deliver medication in a "smart" paper blister package which incorporates an electronic module and printed sensor grid inside the package, both of which are invisible to the patient. The hidden technology records the time, date and location when a dose is removed from the blister package and will be coupled with a POC troponin testing device in each hole for patients with CHD.

What are the benefits or impact of your innovation?

Reduces mortality Reduces need for further treatment Reduces adverse events Reduces risks, side effects or complications Prevents a condition occurring or exacerbating Avoids a test, procedure or unnecessary treatment Enables a test, procedure or treatment to be done non-invasively Increases self-management Increases quality of life Enables shared care Alleviates pain Other benefits for patients and people Reduces the length of stay or enables earlier discharge Reduces need for adult or paediatric critical care Reduces emergency admissions Changes delivery of care from secondary care(for example hospitals) to primary care(for example GP or community services) Change in delivery of care from inpatient to day case Increases compliance Improves patient management or coordination of care or services Reduces referrals Takes less time Leads to fewer appointments Uses no staff or a lower grade of staff Is cost saving Increases efficiency Improves performance Reduces carbon emissions and supports the NHS to achieve net zero Other environmental benefits Other benefits for the NHS and social care

What diseases or conditions does your innovation impact?

Cardiovascular conditions - Acute coronary syndromes Mental health and behavioural conditions - Dementia

Describe the market research you have done, or are doing, within the UK market

Blister packs are very commonly used by patients with multiple different medications

References:

NHS Innovation Service